The promise and pitfalls of antipsychotic co-initiation in schizophrenia
- PMID: 35276078
- DOI: 10.1016/S2215-0366(22)00069-4
The promise and pitfalls of antipsychotic co-initiation in schizophrenia
Conflict of interest statement
I report grants from Daiichi Sankyo and Novartis Pharma; speaker's fees from EA Pharma, Kyowa, Janssen, Lundbeck, Meiji Seika Pharma, Mochida, Otsuka, Sumitomo Dainippon Pharma, Takeda, and Yoshitomiyakuhin; and advisory board fees from Janssen, Mitsubishi Tanabe Pharma, and Sumitomo Dainippon Pharma.
Comment on
-
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.Lancet Psychiatry. 2022 Apr;9(4):291-306. doi: 10.1016/S2215-0366(22)00032-3. Epub 2022 Mar 8. Lancet Psychiatry. 2022. PMID: 35276079 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical